parkinsons

Researchers at UT Southwestern Medical Center studying Parkinson's disease have discovered a previously unrecognized sequence of abnormal activity across multiple regions of the brain, providing a new level of understanding that could improve treatment options.

Researchers are finding ways to target the toxic proteins involved in neurodegenerative diseases such as Parkinson’s and Alzheimer’s that were once considered ‘undruggable.’

This sign of neurodegenerative disease often appears much earlier than other symptoms.

Scientists have pinpointed a brain network—and its distinctive electrical rhythm—that appears to drive the benefits of deep brain stimulation for Parkinson’s disease. The discovery could lead to more precise, personalized stimulation settings and better results for patients.

Scientists have found a new way to stimulate areas deep inside the brain without permanently placing electrical wires there. In mice with Parkinson’s-like movement problems, tiny magnetic particles helped improve movement when the animals were exposed to a magnetic field. The approach could one day offer an alternative to deep brain stimulation, a treatment already […] The post Magnetic Particles…

A team co-led by UT Southwestern Medical Center researchers has identified cellular and molecular mechanisms that could explain the effects of deep brain stimulation (DBS), a therapy used to treat movement disorders including Parkinson's disease and essential tremor. The findings, published in Nature, could lead to new and better ways to apply this treatment.

A future treatment for Parkinson’s disease might use magnetism instead of a permanently implanted brain pacemaker. Scientists have shown that microscopic magnetic plates placed inside the brains of mice can be activated from outside the head and improve Parkinson’s-like movement problems. The experiment combines two simple ideas in an unusual way. Magnetic fields can pass […] The post Could a Mag…

Researchers have developed a synthetic molecule called SK-129 that blocks toxic protein clumps linked to Parkinson’s disease. In mice, the lab-designed molecule reduced disease symptoms by targeting flexible, previously "undruggable" proteins in the brain.

Researchers studied <i>LRRK2 </i> mutations in Parkinson’s disease. The mutations disrupted dopamine release in vulnerable neurons prior to neuronal loss, identifying potential targets and timing for intervention.

Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The post Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this mate…

People exposed to the highest levels of air pollution are about twice as likely to develop Parkinson’s disease dementia or Lewy body disease as those exposed to the lowest levels. Researchers cannot prove that pollution is the cause, but the findings suggest that one of the few risk factors that societies can actually change may influence brain health.

Scientists may have found a way to help brain cells fight back against Parkinson’s disease instead of simply slowing the symptoms. In research published in Science Signaling, a team from Stanford Medicine restored important communication between brain cells in mice by switching off a harmful enzyme. The discovery could open the door to treatments that […] The post Scientists Discover How Damaged …

Living with Parkinson’s disease often means that symptoms change from hour to hour. A person may walk quite normally after taking medication but develop slower steps, shorter strides, or balance problems as the medicine wears off. Because most medical appointments last only a short time, doctors may not always see these changes. Researchers have therefore […] The post Scientists develop ‘invisibl…

Synucleinopathies are a group of neurodegenerative disorders that include serious conditions such as Parkinson’s disease and dementia with Lewy bodies. There are currently no cures for these disorders, and treatment is limited to mitigating symptoms. Recently, antibody-based therapies have attracted considerable attention, but alternative approaches are still necessary. Therapy development for sy…

For decades, Parkinson’s disease treatment has focused mainly on replacing dopamine or easing movement problems. While these medicines improve daily life, they cannot prevent the gradual loss of brain cells that causes the disease to worsen. Researchers have therefore been searching for treatments that attack the disease at its source instead of only controlling symptoms. […] The post Scientists …

A protein associated with Parkinson’s disease can move from one brain cell to another. Yale researchers have now identified an interacting pair of proteins that appears to help it cross the cell membrane and contribute to neuronal damage. The proteins, mGluR4 and NPDC1, are found on the surfaces of dopamine-producing neurons in the substantia nigra, the brain region whose deterioration causes man…

Differing gene expression patterns could be to blame The post Why Do Men Develop Parkinson’s Disease More Often Than Women? appeared first on Nautilus .

Parkinson’s disease is the second most common brain disease that causes the gradual loss of nerve cells, affecting more than 10 million people worldwide. It mainly damages brain cells that produce dopamine, a chemical that helps control movement. As these cells die, people develop shaking, stiffness, slow movement, poor balance, and difficulty walking. Many patients […] The post A Promising Drug …

A large genetic study suggests that Alzheimer’s disease and Parkinson’s disease are linked to the body’s metabolism in strikingly different ways. That may help explain why metabolic treatments, including GLP-1-based drugs, do not necessarily have the same effects across neurodegenerative diseases.